This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Fossum, E. Search for Related Content PubMed PubMed Citation Articles by Fossum, E.

The Effect of Losartan Versus Atenolol on Cardiovascular Morbidity and Mortality in Patients With Hypertension Taking Aspirin

The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study

Eigil Fossum, MD, PhD^_*,_*, Andreas Moan, MD, PhD, Sverre E. Kjeldsen, MD, PhD^_*,, Richard B. Devereux, MD, FACC, Stevo Julius, MD, ScD, Steven M. Snapinn, PhD^||, Jonathan M. Edelman, MD^||, Ulf de Faire, MD, PhD^¶, Frej Fyhrquist, MD, PhD^#, Hans Ibsen, MD, PhD^_**, Krister Kristianson, PhD, Ole Lederballe-Pedersen, MD, PhD, Lars H. Lindholm, MD, PhD, Markku S. Nieminen, MD, FACC^#, Per Omvik, MD, PhD^||||, Suzanne Oparil, MD, FACC^¶¶, Hans Wedel, PhD^##, Björn Dahlöf, MD, PhD^_*** for the LIFE Study Group

^_* Department of Cardiology, Ullevaal University Hospital, Oslo, Norway
MSD, Drammen, Norway
Department of Cardiology, University of Michigan, Ann Arbor, Michigan
Division of Cardiology, Cornell Medical Center, New York, New York
^|| Merck and Co., Inc., Whitehouse Station, New Jersey
^¶ Department of Medicine, Karolinska University Hospital, Stockholm, Sweden
^# Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
^_** Department of Internal Medicine, Glostrup University Hospital, Glostrup, Denmark
Merck Research Laboratories Scandinavia, Stockholm, Sweden
Department of Internal Medicine, Viborg Hospital, Viborg, Denmark
Department of Family Medicine, Umeå University, Umeå, Sweden
^|||| Department of Cardiology, Haukeland University Hospital, Bergen, Norway
^¶¶ Department of Medicine, University of Alabama, Birmingham, Alabama
^## The Nordic School of Public Health, Göteborg, Sweden
^_*** Department of Medicine, Sahlgrenska University Hospital/Östra, Göteborg, Sweden

View larger version (31K): [in a new window]   Figure 1 (A) Kaplan-Meier curves for the primary end point; p = 0.016 for aspirin interaction. (B) Kaplan-Meier curves for cardiovascular death. (C) Kaplan-Meier curves for stroke. (D) Kaplan-Meier curves for myocardial infarction; p = 0.037 for aspirin interaction.